A provider briefing on Breyna availability in 2026 — supply timeline, prescribing implications, alternatives, and tools to help patients find stock.
Breyna (Budesonide/Formoterol Fumarate Dihydrate) — the first FDA-approved generic of Symbicort — has become a cornerstone of maintenance therapy for asthma and COPD since its 2023 launch. But as prescribers, you've likely heard from patients struggling to fill their prescriptions. This briefing provides a comprehensive update on supply status, cost considerations, and actionable strategies to support your patients.
Understanding the history helps contextualize current availability:
Viatris, in partnership with Kindeva Drug Delivery, launched Breyna in July 2023 as the first ANDA-approved generic of AstraZeneca's Symbicort. Initial uptake was strong — both patients and payers welcomed a lower-cost alternative. However, the broader Budesonide/Formoterol inhaler supply was already strained, with Symbicort experiencing intermittent shortages and wholesaler allocation limits creating uneven distribution.
Intermittent shortages persisted through 2024. The FDA monitored the situation but did not place Budesonide/Formoterol products on the critical shortage list. Wholesaler allocations continued to create regional disparities, with some areas more affected than others. Seasonal demand surges during respiratory season compounded the issue.
Additional generic Budesonide/Formoterol inhalers entered the market in 2025, easing demand pressure on both Breyna and brand-name Symbicort. Supply improved but remained inconsistent in certain regions, particularly rural areas and smaller pharmacy networks.
As of early 2026, Breyna is not on the FDA's critical drug shortage list. National supply has stabilized compared to prior years. However, spot shortages continue at the pharmacy level — particularly during October through March respiratory season and in areas served by fewer distributors.
The availability picture affects prescribing decisions in several practical ways:
Breyna has been added to the preferred tier of many commercial and Medicare Part D formularies as a cost-effective generic alternative. However, formulary status varies by plan. Before prescribing, consider verifying the patient's specific formulary to determine whether Breyna, generic Budesonide/Formoterol, or brand-name Symbicort is preferred.
Some plans require prior authorization for ICS/LABA inhalers or mandate step therapy (e.g., requiring trial of an ICS alone before approving a combination product). Breyna's generic status may reduce prior authorization requirements compared to brand-name Symbicort, but this varies by payer.
Breyna is rated AB by the FDA to Symbicort, meaning it is considered therapeutically equivalent. Pharmacists can substitute Breyna for Symbicort prescriptions (and vice versa) without a new prescription in most states, unless the prescriber specifies "Dispense as Written."
While national supply has improved, patients report the following challenges:
Understanding the cost landscape helps you guide patients toward affordable options:
Several resources can help you and your staff support patients experiencing access difficulties:
Medfinder offers real-time pharmacy stock data that you or your staff can use to help patients locate Breyna. Rather than asking patients to call pharmacy after pharmacy, you can direct them to this tool or use it during the visit to identify a pharmacy with stock.
If the patient's preferred pharmacy is out of stock, consider sending the prescription to an alternate pharmacy identified through Medfinder. Many EHR systems support routing prescriptions to multiple pharmacies.
When Breyna is unavailable, these ICS/LABA alternatives can be considered:
For patient-facing information on alternatives, you can share our guide: Alternatives to Breyna.
Consider sharing these resources with patients:
The outlook for Breyna availability is cautiously optimistic. Factors working in favor of improved supply include:
However, metered-dose inhaler manufacturing remains complex, and seasonal demand fluctuations will likely continue to cause localized disruptions. Proactive prescribing — including identifying backup alternatives and educating patients on refill timing — remains important.
Breyna has become an important option in the ICS/LABA landscape, particularly for cost-conscious patients and payers. While supply has improved substantially since 2023, your patients may still encounter availability challenges. By staying informed on supply trends, utilizing tools like Medfinder for Providers, and maintaining familiarity with therapeutic alternatives, you can help ensure continuity of care for your respiratory patients.
For related clinical resources, see our provider guide on how to help your patients find Breyna in stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
